Transgene shares surge 20% on positive Phase 1 head-and-neck cancer vaccine data
Transgene EURONEXT:TNG shares jumped 20% in early Paris trading after the French biotech reported positive Phase 1 trial data on its head-and-neck cancer vaccine candidate.